Once Daily 3TC, Efavirenz and ddI for HIV Infection
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a
randomised, multi-centre, open-label study in well-controlled treatment-experienced
HIV-infected patients to assess compliance with a once-daily regimen of antiretroviral
therapy versus continuation of current anti-retroviral regimen delivered at least twice
daily.